BioSpace News Archive

Arecor Therapeutics plc announces that its ultra-concentrated, ultra-rapid acting insulin candidate, AT278, met all primary and secondary endpoints, and also demonstrated superiority to NovoRapid® and Humulin® R U-500, in a Phase I clinical trial in Type 2 diabetics with a high body mass index.

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Sol-Gel Technologies, Ltd. today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

BPGbio announced today the publication of a significant, multi-year research effort titled “ Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson’s disease biomarker panel” in Scientific Reports.

Septerna today announced that the company will present the first preclinical data on the company’s parathyroid hormone 1 receptor (PTH1R) and thyroid stimulating hormone receptor (TSHR) programs at the Endocrine Society’s Annual Meeting (ENDO 2024) held June 1-4 in Boston.

Beaconcure Inc. announces a strategic partnership with Phastar Inc., a global specialist biometrics contract research organization (CRO), to enhance clinical review processes in clinical trials.

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the publication of the results of preclinical studies in ACS Chemical Neuroscience that validate the decisions to pursue RE104, a proprietary, patented prodrug of 4-OH-DiPT as a potential therapeutic in depressive disorders.

Biora Therapeutics, Inc. presented a poster titled “Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC” at the Digestive Disease Week® conference in Washington DC, on Sunday, May 19, 2024.

60 Degrees Pharmaceuticals, Inc. announced today it will fund Babesia spp testing in chronic fatigue patient samples in a study to be conducted by North Carolina State College of Veterinary Medicine.

Candel Therapeutics, Inc. today announced it will be hosting a webcasted R&D breakfast panel featuring prominent scientific and medical thought leaders to discuss topline overall survival data from its phase 2 clinical trial of CAN-2409.